Strategas宏观主题机会主动型ETF SAMT 深 沪
交易中 04-01 11:09:22 美东时间
39.6291
+0.359
+0.91%
华盛通- 最 高39.6291
- 今 开39.56
- 成交量 1.77万股
- 最 低 39.4904
- 昨 收 39.27
- 总市值 5.24亿
- 52周最高 42.0854
- 市盈率 静 --
- 换手率 0.13%
- 52周最低 27.7399
- 委 比 -1.96%
- 总股本 1321.84万
- 历史最高 42.0854
- 量 比 0.77
- 振 幅 0.35%
- 历史最低 20.1774
- 每 手 1
- 风险率 3.64%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Cencora CFO Jim Cleary To Retire After Years Of Driving Growth
COR stock dips as Cencora announces CFO James Cleary's retirement. Read the full details on the leadership search and 2026 financial outlook.
03-17 23:12
BRIEF-Royalty Pharma Acquires Royalty Interest In Nuvalent’S Neladalkib And Zidesamtinib For Up To $315 Million
Dec 16 (Reuters) - Royalty Pharma PLC RPRX.O: ROYALTY PHARMA ACQUIRES ROYALTY INTEREST IN NUVALENT’S NELADALKIB AND ZIDESAMTINIB FOR UP TO $315 MILLION ROYALTY PHARMA - ROYALTY DURATION FOR BOTH THERA...
2025-12-16 20:18
BRIEF-Nuvalent Announces FDA Acceptance Of New Drug Application For Zidesamtinib For The Treatment Of TKI Pre-Treated Patients With Advanced ROS1-positive NSCLC
Nov 19 (Reuters) - Nuvalent Inc NUVL.O: NUVALENT ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION FOR ZIDESAMTINIB FOR THE TREATMENT OF TKI PRE-TREATED PATIENTS WITH ADVANCED ROS1-POSITIVE NSCLC NUVAL...
2025-11-20 05:47
BRIEF-Nuvalent Announces Positive Pivotal Data From Arros-1 Clinical Trial Of Zidesamtinib
June 24 (Reuters) - Nuvalent Inc NUVL.O: NUVALENT ANNOUNCES POSITIVE PIVOTAL DATA FROM ARROS-1 CLINICAL TRIAL OF ZIDESAMTINIB FOR TKI PRE-TREATED PATIENTS WITH ADVANCED ROS1-POSITIVE NSCLC NUVALENT IN...
2025-06-24 18:34
